The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015
Open accessAbstract
IMPORTANCE Liver cancer is among the leading causes of cancer deaths globally.The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use.OBJECTIVE To report results of the Global Burden of Disease (GBD) 2015 study on primary liver cancer incidence, mortality, and disability-adjusted life-years (DALYs) for 195 countries or territories from 1990 to 2015, and present global, regional, and national estimates on the burden of liver cancer attributable to HBV, HCV, alcohol, and an "other" group that encompasses residual causes. DESIGN, SETTINGS, AND PARTICIPANTSMortality was estimated using vital registration and cancer registry data in an ensemble modeling approach.Single-cause mortality estimates were adjusted for all-cause mortality.Incidence was derived from mortality estimates and the mortality-to-incidence ratio.Through a systematic literature review, data on the proportions of liver cancer due to HBV, HCV, alcohol, and other causes were identified.Years of life lost were calculated by multiplying each death by a standard life expectancy.Prevalence was estimated using mortality-to-incidence ratio as surrogate for survival.Total prevalence was divided into 4 sequelae that were multiplied by disability weights to derive years lived with disability (YLDs).DALYs were the sum of years of life lost and YLDs. MAIN OUTCOMES AND MEASURESLiver cancer mortality, incidence, YLDs, years of life lost, DALYs by etiology, age, sex, country, and year. RESULTSThere were 854 000 incident cases of liver cancer and 810 000 deaths globally in 2015, contributing to 20 578 000 DALYs.Cases of incident liver cancer increased by 75% between 1990 and 2015, of which 47% can be explained by changing population age structures, 35% by population growth, and -8% to changing age-specific incidence rates.The male-to-female ratio for age-standardized liver cancer mortality was 2.8.Globally, HBV accounted for 265 000 liver cancer deaths (33%), alcohol for 245 000 (30%), HCV for 167 000 (21%), and other causes for 133 000 (16%) deaths, with substantial variation between countries in the underlying etiologies. CONCLUSIONS AND RELEVANCELiver cancer is among the leading causes of cancer deaths in many countries.Causes of liver cancer differ widely among populations.Our results show that most cases of liver cancer can be prevented through vaccination, antiviral treatment, safe blood transfusion and injection practices, as well as interventions to reduce excessive alcohol use.In line with the Sustainable Development Goals, the identification and elimination of risk factors for liver cancer will be required to achieve a sustained reduction in liver cancer burden.The GBD study can be used to guide these prevention efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
International Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,435
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Self-citationWang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Self-citationGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Body Fatness and Cancer — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1606602 · Cited by 3,596
Fitzmaurice, C., & Global Burden of Disease Cancer Collaboration (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1568 · Cited by 1,646
Self-citationGlobal burden of cancers attributable to infections in 2012: a synthetic analysis
Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30143-7 · Cited by 1,635
Salomon, J. A., Vos, T., Hogan, D. R., Gagnon, M., Naghavi, M., Mokdad, A., Begum, N., Shah, R., Karyana, M., Kosen, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61680-8 · Cited by 1,322
Self-citationGlobal burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment
Liu, Y., & Wu, F. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901388 · Cited by 1,224
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Modeling causes of death: an integrated approach using CODEm
Foreman, K. J., Lozano, R., Lopez, A. D., & Murray, C. J. (2012) · Population Health Metrics · doi:10.1186/1478-7954-10-1 · Cited by 564
Self-citationGlobal burden of human food-borne trematodiasis: a systematic review and meta-analysis
Fürst, T., Keiser, J., & Utzinger, J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70294-8 · Cited by 559
Self-citationHepatocellular carcinoma epidemiology
Bosetti, C., Turati, F., & La Vecchia, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.08.007 · Cited by 530
World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma
de Martel, C., Maucort‐Boulch, D., Plummer, M., & Franceschi, S. (2015) · Hepatology · doi:10.1002/hep.27969 · Cited by 503
The Global Epidemiology of Hepatocellular Carcinoma: Present and Future
McGlynn, K. A., & London, W. T. (2011) · Clinics in Liver Disease · doi:10.1016/j.cld.2011.03.006 · Cited by 471
Requirements for global elimination of hepatitis B: a modelling study
Nayagam, S., Thursz, M., Sicuri, E., Conteh, L., Wiktor, S., Low-Beer, D., & Hallett, T. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30204-3 · Cited by 373
Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection
Chuang, S.-C., Vecchia, C. L., & Boffetta, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.10.040 · Cited by 365
International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007
Petrick, J. L., Braunlin, M., Laversanne, M., Valery, P. C., Bray, F., & McGlynn, K. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30211 · Cited by 342
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
Makarova‐Rusher, O. V., Altekruse, S. F., McNeel, T. S., Ulahannan, S., Duffy, A. G., Graubard, B. I., Greten, T. F., & McGlynn, K. A. (2016) · Cancer · doi:10.1002/cncr.29971 · Cited by 332
International Trends in Liver Cancer Incidence Rates
Center, M. M., & Jemal, A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0643 · Cited by 309
Cohen, C., Holmberg, S. D., McMahon, B. J., Block, J. M., Brosgart, C. L., Gish, R. G., London, W. T., & Block, T. M. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01401.x · Cited by 174
The Increasing Burden of Imported Chronic Hepatitis B — United States, 1974–2008
Mitchell, T., Armstrong, G. L., Hu, D. J., Wasley, A., & Painter, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027717 · Cited by 131
Attributable Causes of Liver Cancer Mortality and Incidence in China
Fan, J., Wang, J.-B., Jiang, Y. L., Xiang, W., Liang, H., Wei, W., Qiao, Y., & Boffetta, P. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7251 · Cited by 115
Ahern, R. M., Lozano, R., Naghavi, M., Foreman, K., Gakidou, E., & Murray, C. J. (2011) · Population Health Metrics · doi:10.1186/1478-7954-9-8 · Cited by 106
Self-citationSun, Z., Chen, T., Thorgeirsson, S. S., Zhan, Q., Chen, J., Park, J., Lu, P., Hsia, C. C., Wang, N.-J., Xu, L., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt007 · Cited by 99
Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs
Ward, J. W., & Mermin, J. (2015) · New England Journal of Medicine · doi:10.1056/nejme1513245 · Cited by 87
Guirguis, J. K., Chhatwal, J., Dasarathy, J., Rivas, J. M., McMichael, D., Nagy, L. E., McCullough, A. J., & Dasarathy, S. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12887 · Cited by 86
Chimed, T., Sandagdorj, T., Znaor, A., Laversanne, M., Tseveen, B., Purevsuren, G., & Bray, F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30463 · Cited by 76
Advanced Hepatocellular Cancer: the Current State of Future Research
Connell, L. C., Harding, J. J., & Abou‐Alfa, G. K. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0415-3 · Cited by 64
The accuracy of liver cancer as the underlying cause of death on death certificates.
Percy, C. L., Ries, L. G., & Holten, V. (1990) · PubMed · Cited by 52
Chang, I., Huang, S.-F., Chen, P., Chen, C., Chen, C., Wu, C.-C., Tsai, C., Lee, P., Chen, M., Lee, C., et al. (2016) · Medicine · doi:10.1097/md.0000000000003284 · Cited by 42
Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population
Hao, X., Wang, P., Chen, K., Li, Q., He, M., Yu, S. B., Guo, Z., Perruccio, A. V., & Rohan, T. E. (2003) · European Journal of Cancer Prevention · doi:10.1097/00008469-200308000-00006 · Cited by 32
Etiological and molecular profile of hepatocellular cancer from India
Asim, M., Sarma, M. P., & Kar, P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27993 · Cited by 28
Polednak, A. P. (2013) · PubMed · Cited by 8
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Self-citationCao, W., Chen, H.-D., Yu, Y.-W., Li, N., & Chen, W.-Q. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001474 · Cited by 2,865
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Metadata
- Authors
- Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., Artaman, A., Ayele, T. A., Barac, A., Bensenor, I., Berhane, A., Bhutta, Z., Castillo-Rivas, J., Chitheer, A., Choi, J.-Y., Cowie, B., Dandona, L., Dandona, R., Dey, S., Dicker, D., Phuc, H., Ekwueme, D. U., Zaki, M. E. S., Fischer, F., Fürst, T., Hancock, J., Hay, S. I., Hotez, P., Jee, S. H., Kasaeian, A., Khader, Y., Khang, Y.-H., Kumar, G. A., Kutz, M., Larson, H., Lopez, A., Lunevicius, R., Malekzadeh, R., McAlinden, C., Meier, T., Mendoza, W., Mokdad, A., Moradi-Lakeh, M., Nagel, G., Nguyen, Q., Nguyen, G., Ogbo, F., Patton, G., Pereira, D. M., Pourmalek, F., Qorbani, M., Radfar, A., Roshandel, G., Salomon, J. A., Sanabria, J., Sartorius, B., Satpathy, M., Sawhney, M., Sepanlou, S., Shackelford, K., Shore, H., Sun, J., Mengistu, D. T., Topór-Madry, R., Tran, B., Ukwaja, K. N., Vlassov, V., Vollset, S. E., Vos, T., Wakayo, T., Weiderpass, E., Werdecker, A., Yonemoto, N., Younis, M., Yu, C., Zaidi, Z., Zhu, L., Murray, C. J. L., Naghavi, M., & Fitzmaurice, C.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1683
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2761031851
- Cited by
- 1,987
- References
- 41
- FWCI
- 56.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.